Contact this trialFirst, we need to learn more about you.
Checkpoint Inhibitor
Nivolumab + Relatlimab for Advanced Cancer
Recruiting1 awardPhase 2
Baltimore, Maryland
This trial is testing a new combination drug treatment for patients with MSI-H solid tumors who have not responded to other PD-(L)1 treatments.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.